However, the utilisation of our quantification method in this format demonstrates what we believe to be its primary use, prioritising potentially pathogenic newly identified FTD- or ALS-associated variants in genes other than FUS and TARDBP for more in-depth investigation. This evidence concerns the gene FUS and amyotrophic lateral sclerosis.